Sairopa is a clinical-stage biotechnology company focused on developing innovative cancer treatments by modulating the immune system. The company has a strong emphasis on enhancing the cancer-immunity cycle, which involves various critical processes such as tumor-antigen release, T-cell activation, and overcoming local immunosuppression within tumors. Sairopa's proprietary therapeutic antibodies, including ADU-1805 (an anti-SIRPalpha antibody) and ADU-1604 (an anti-CTLA4 antibody), are designed to improve the immune response against tumors. ADU-1604 is currently undergoing Phase 1 clinical trials for patients with advanced melanoma, demonstrating promising early clinical efficacy and a favorable safety profile.

The company’s advancements are supported by a strategic acquisition of a portfolio of therapeutic antibodies from Chinook Therapeutics, which were initially developed using the proprietary B-Select antibody platform. This platform has been instrumental in identifying other notable antibodies, such as pembrolizumab (Keytruda™). With a dedicated team of experts in immune oncology and a commitment to clinical development, Sairopa aims to deliver effective cancer immunotherapies that can significantly benefit patients and improve outcomes in oncology.

Netherlands

Sairopa develops novel treatments for cancer by modulating the patient’s immune system. Early 2021 Sairopa acquired, backed by a reputable biotech investor, a portfolio of therapeutic antibodies from an American public company. Sairopa will enter clinical testing of two of its lead compounds in Phase 1 clinical trials in 2022. The company is based in Rotterdam, the Netherlands but operates internationally & virtually. To advance our programs, we are looking for a project manager that wants to make a difference and has a pioneer’s mentality.

Sairopa

Company Details